PE20211657A1 - Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato - Google Patents
Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumaratoInfo
- Publication number
- PE20211657A1 PE20211657A1 PE2021000720A PE2021000720A PE20211657A1 PE 20211657 A1 PE20211657 A1 PE 20211657A1 PE 2021000720 A PE2021000720 A PE 2021000720A PE 2021000720 A PE2021000720 A PE 2021000720A PE 20211657 A1 PE20211657 A1 PE 20211657A1
- Authority
- PE
- Peru
- Prior art keywords
- tablet
- tenofovir disoproxil
- disoproxil fumarate
- hcl
- rilpivirin
- Prior art date
Links
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 title abstract 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract 2
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 2
- 229960001021 lactose monohydrate Drugs 0.000 abstract 2
- 235000019359 magnesium stearate Nutrition 0.000 abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 2
- 230000036470 plasma concentration Effects 0.000 abstract 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 abstract 1
- 229920000881 Modified starch Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 229960000366 emtricitabine Drugs 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 229960002814 rilpivirine Drugs 0.000 abstract 1
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invencion se refiere a un comprimido que comprende una primera y segunda capa, en donde: i) la primera capa comprende: 27,5 mg/comprimido de Rilpivirina HCl; 60,0 mg/comprimido de Celulosa microcristalina; 189,8 mg/comprimido de Monohidrato de lactosa; 3,3 mg/comprimido de Povidona; 0,4 mg/comprimido de Polisorbato 20; 16,1 mg/comprimido de Croscarmelosa sodica y 3,0 mg/comprimido de Estearato de magnesio, y ii) la segunda capa comprende: 200,0 mg/comprimido de Emtricitabina; 300,0 mg/comprimido de Tenofovir disoproxil fumarato; 150,0 mg/comprimido de Celulosa microcristalina; 80,0 mg/comprimido de Monohidrato de lactosa; 50,0 mg/comprimido de Almidon pregelatinizado; 60,0 mg/comprimido de Croscarmelosa sodica y 10,0 mg/comprimido de Estearato de magnesio. Ademas, el comprimido posee 34,5 mg de un recubrimiento. Dicho comprimido tiene estabilidad quimica adecuada para los principios activos y produce concentraciones en plasma de cada uno de los tres agentes que son equivalentes a las concentraciones en plasma producidas mediante la administracion de dichos agentes individualmente, siendo util en el tratamiento de infecciones virales tales como el VIH.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41560010P | 2010-11-19 | 2010-11-19 | |
| PCT/US2011/061515 WO2012068535A1 (en) | 2010-11-19 | 2011-11-18 | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211657A1 true PE20211657A1 (es) | 2021-08-24 |
Family
ID=45094284
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013001214A PE20140163A1 (es) | 2010-11-19 | 2011-11-18 | Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato |
| PE2021000720A PE20211657A1 (es) | 2010-11-19 | 2011-11-18 | Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato |
| PE2016002828A PE20170521A1 (es) | 2010-11-19 | 2011-11-18 | Combinacion farmaceutica que comprende rilpivirina hcl, tenofovir disoproxil fumarato y emtricitabina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013001214A PE20140163A1 (es) | 2010-11-19 | 2011-11-18 | Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016002828A PE20170521A1 (es) | 2010-11-19 | 2011-11-18 | Combinacion farmaceutica que comprende rilpivirina hcl, tenofovir disoproxil fumarato y emtricitabina |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US10857102B2 (es) |
| EP (2) | EP2640362B2 (es) |
| JP (2) | JP2014500261A (es) |
| KR (1) | KR101923103B1 (es) |
| CN (2) | CN103491948B (es) |
| AP (1) | AP3816A (es) |
| AR (2) | AR084500A1 (es) |
| AU (3) | AU2011329642B2 (es) |
| BR (1) | BR112013012245B1 (es) |
| CA (1) | CA2818097C (es) |
| CL (1) | CL2013001402A1 (es) |
| CO (1) | CO6761300A2 (es) |
| CR (1) | CR20130293A (es) |
| DK (1) | DK2640362T4 (es) |
| EA (2) | EA025852B1 (es) |
| EC (2) | ECSP13012700A (es) |
| ES (1) | ES2524408T5 (es) |
| HK (1) | HK1206592A1 (es) |
| HR (1) | HRP20140946T1 (es) |
| IL (1) | IL226300B (es) |
| MA (1) | MA34735B1 (es) |
| ME (1) | ME01980B (es) |
| MX (1) | MX347512B (es) |
| MY (1) | MY185604A (es) |
| NZ (1) | NZ610729A (es) |
| PE (3) | PE20140163A1 (es) |
| PH (1) | PH12013501002A1 (es) |
| PL (1) | PL2640362T5 (es) |
| PT (1) | PT2640362E (es) |
| RS (1) | RS53691B1 (es) |
| SG (3) | SG10201509521WA (es) |
| SM (1) | SMT201400150B (es) |
| TW (1) | TWI556840B (es) |
| UA (1) | UA114075C2 (es) |
| WO (1) | WO2012068535A1 (es) |
| ZA (1) | ZA201304481B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201100293A1 (ru) | 2003-01-14 | 2011-08-30 | Джилид Сайэнс, Инк. | Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| AP3816A (en) | 2010-11-19 | 2016-09-30 | Gilead Sciences Inc | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
| SMT201600476T1 (it) | 2011-08-16 | 2017-03-08 | Gilead Sciences Inc | Tenofovir alafenammide emifumarato |
| CA2779052A1 (en) * | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| PE20151499A1 (es) | 2012-12-21 | 2015-10-29 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico |
| EP2832351A1 (en) * | 2013-07-29 | 2015-02-04 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multilayer Tablet Formulations Comprising Tenofovir and Entecavir |
| CZ2013985A3 (cs) * | 2013-12-09 | 2015-06-17 | Zentiva, K.S. | Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát |
| WO2015152433A1 (en) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| US20190022116A1 (en) | 2014-12-26 | 2019-01-24 | Emory University | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto |
| US9839212B2 (en) | 2015-04-16 | 2017-12-12 | Bio-Lab, Inc. | Multicomponent and multilayer compacted tablets |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| KR20170003063A (ko) * | 2015-06-30 | 2017-01-09 | 한미약품 주식회사 | 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법 |
| SI3346995T1 (sl) * | 2015-11-09 | 2019-11-29 | Gilead Sciences Inc | Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti |
| WO2017175855A1 (en) * | 2016-04-08 | 2017-10-12 | Shionogi & Co., Ltd. | Stabilized solid dosage form |
| TR201617448A2 (tr) * | 2016-11-29 | 2018-06-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler |
| US10561614B2 (en) * | 2017-01-27 | 2020-02-18 | Steerlife India Private Limited | Tenofovir granules |
| CA3067147A1 (en) | 2017-06-30 | 2019-01-03 | Viiv Healthcare Company | Combination and uses and treatments thereof |
| DK3706762T3 (da) | 2017-12-07 | 2024-12-16 | Univ Emory | N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil |
| BR112021026916A2 (pt) * | 2019-07-03 | 2022-05-10 | Janssen Sciences Ireland Unlimited Co | Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina |
| CN112137981A (zh) * | 2020-11-02 | 2020-12-29 | 成都晶富医药科技有限公司 | 富马酸丙酚替诺福韦片及其制备工艺 |
| WO2024211882A1 (en) * | 2023-04-07 | 2024-10-10 | Navinta, Llc | Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents |
| CN119174735A (zh) * | 2024-09-03 | 2024-12-24 | 安徽贝克生物制药有限公司 | 一种含利匹韦林的复方片及制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ250842A (en) | 1991-02-22 | 1996-03-26 | Univ Emory | Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc) |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| WO2003045327A2 (en) | 2001-11-27 | 2003-06-05 | Bristol-Myers Squibb Company | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| EA201100293A1 (ru) * | 2003-01-14 | 2011-08-30 | Джилид Сайэнс, Инк. | Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции |
| DK1632232T6 (da) | 2004-09-02 | 2022-04-19 | Janssen Pharmaceutica Nv | Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril |
| WO2006024668A1 (en) | 2004-09-02 | 2006-03-09 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
| TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| EP1933815A2 (en) | 2005-10-14 | 2008-06-25 | Microdose Technologies Inc. | Pharmaceutical packaging of an oral dosage combination |
| AP2008004533A0 (en) | 2005-12-14 | 2008-08-31 | Cipla Ltd | Pharmaceutical combination |
| PL2487161T5 (pl) * | 2007-02-23 | 2024-09-09 | Gilead Sciences, Inc. | <div>Modulatory właściwości farmakokinetycznych środków terapeutycznych</div><div> </div> |
| WO2008140461A1 (en) | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
| US20080286344A1 (en) | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
| CN101778855A (zh) * | 2007-05-22 | 2010-07-14 | 阿尔迪默菲克斯技术有限责任公司 | 替诺福韦酯半富马酸共晶体 |
| WO2009037449A1 (en) | 2007-09-18 | 2009-03-26 | Cipla Limited | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors |
| WO2009106960A2 (en) | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
| PL2296633T3 (pl) | 2008-05-02 | 2016-03-31 | Gilead Sciences Inc | Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego |
| AP3250A (en) | 2009-02-06 | 2015-05-31 | Gilead Sciences Inc | Tablets for combination therapy |
| EA201200525A1 (ru) | 2009-09-21 | 2012-09-28 | Гайлид Сайэнсиз, Инк. | 2'-фторзамещенные карба-нуклеозидные аналоги для противовирусного лечения |
| WO2011077100A1 (en) | 2009-12-24 | 2011-06-30 | Cipla Limited | Antiretroviral composition |
| AP3816A (en) | 2010-11-19 | 2016-09-30 | Gilead Sciences Inc | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
-
2011
- 2011-11-18 AP AP2013006931A patent/AP3816A/en active
- 2011-11-18 TW TW100142311A patent/TWI556840B/zh active
- 2011-11-18 KR KR1020137015719A patent/KR101923103B1/ko active Active
- 2011-11-18 RS RS20140668A patent/RS53691B1/sr unknown
- 2011-11-18 PH PH1/2013/501002A patent/PH12013501002A1/en unknown
- 2011-11-18 EA EA201390651A patent/EA025852B1/ru unknown
- 2011-11-18 PE PE2013001214A patent/PE20140163A1/es not_active Application Discontinuation
- 2011-11-18 PL PL11791161T patent/PL2640362T5/pl unknown
- 2011-11-18 AU AU2011329642A patent/AU2011329642B2/en active Active
- 2011-11-18 MX MX2013005669A patent/MX347512B/es active IP Right Grant
- 2011-11-18 WO PCT/US2011/061515 patent/WO2012068535A1/en not_active Ceased
- 2011-11-18 CN CN201180063666.6A patent/CN103491948B/zh active Active
- 2011-11-18 ES ES11791161T patent/ES2524408T5/es active Active
- 2011-11-18 JP JP2013540085A patent/JP2014500261A/ja not_active Withdrawn
- 2011-11-18 EA EA201691695A patent/EA201691695A1/ru unknown
- 2011-11-18 NZ NZ610729A patent/NZ610729A/en unknown
- 2011-11-18 PE PE2021000720A patent/PE20211657A1/es unknown
- 2011-11-18 EP EP11791161.0A patent/EP2640362B2/en active Active
- 2011-11-18 UA UAA201306403A patent/UA114075C2/uk unknown
- 2011-11-18 PE PE2016002828A patent/PE20170521A1/es unknown
- 2011-11-18 BR BR112013012245-5A patent/BR112013012245B1/pt active IP Right Grant
- 2011-11-18 CN CN201610900183.1A patent/CN106511357A/zh active Pending
- 2011-11-18 SG SG10201509521WA patent/SG10201509521WA/en unknown
- 2011-11-18 CA CA2818097A patent/CA2818097C/en active Active
- 2011-11-18 AR ARP110104318A patent/AR084500A1/es not_active Application Discontinuation
- 2011-11-18 HR HRP20140946AT patent/HRP20140946T1/hr unknown
- 2011-11-18 DK DK11791161.0T patent/DK2640362T4/da active
- 2011-11-18 PT PT117911610T patent/PT2640362E/pt unknown
- 2011-11-18 ME MEP-2014-150A patent/ME01980B/me unknown
- 2011-11-18 SG SG2013038484A patent/SG190333A1/en unknown
- 2011-11-18 SG SG10201912527XA patent/SG10201912527XA/en unknown
- 2011-11-18 US US13/988,072 patent/US10857102B2/en active Active
- 2011-11-18 EP EP14183494.5A patent/EP2826466A1/en not_active Withdrawn
- 2011-11-18 MY MYPI2016001764A patent/MY185604A/en unknown
-
2013
- 2013-05-12 IL IL226300A patent/IL226300B/en active IP Right Grant
- 2013-05-17 CL CL2013001402A patent/CL2013001402A1/es unknown
- 2013-05-28 CO CO13130615A patent/CO6761300A2/es unknown
- 2013-06-14 MA MA36010A patent/MA34735B1/fr unknown
- 2013-06-17 CR CR20130293A patent/CR20130293A/es unknown
- 2013-06-18 EC ECSP13012700 patent/ECSP13012700A/es unknown
- 2013-06-18 ZA ZA2013/04481A patent/ZA201304481B/en unknown
-
2014
- 2014-03-21 HK HK15106347.0A patent/HK1206592A1/en unknown
- 2014-10-16 SM SM201400150T patent/SMT201400150B/xx unknown
-
2015
- 2015-04-20 JP JP2015085594A patent/JP6138851B2/ja active Active
-
2016
- 2016-07-29 AU AU2016208417A patent/AU2016208417B2/en active Active
-
2018
- 2018-04-16 AU AU2018202635A patent/AU2018202635A1/en not_active Abandoned
-
2019
- 2019-10-30 EC ECSENADI201978196A patent/ECSP19078196A/es unknown
-
2020
- 2020-11-19 AR ARP200103214A patent/AR123409A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211657A1 (es) | Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato | |
| PE20200175A1 (es) | Formas de dosificacion de ruxolitinib de liberacion sostenida | |
| EA201591363A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| PE20110994A1 (es) | Comprimidos antivirales que comprenden elvitegravir, emtricitabina, disoproxil fumarato de tenofovir y un derivado de tiazol | |
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| CY1118032T1 (el) | Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| ECSP15022442A (es) | Producto de comicronización que comprende acetato de ulipristal | |
| EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
| EA201291104A1 (ru) | Пероральные лекарственные формы бендамустина | |
| MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| BR112015004091A2 (pt) | formulação de cápsula de compósito farmacêutico que compreende irbesartan e inibidor de hmg-coa redutase | |
| PE20142460A1 (es) | Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel | |
| TR201908151T4 (tr) | İzoindolin türevleri. | |
| MX359436B (es) | Preparacion de combinacion farmaceutica que comprende un inhibidor de hmg-coa reductasa y un inhibidor de la absorcion de colesterol. | |
| TR201310724A2 (tr) | Linagliptinin farmasotik formulasyonları. | |
| IN2013CH05288A (es) | ||
| CO6280050A1 (es) | Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa | |
| UA110792C2 (uk) | Лікарська форма бендамустину для перорального застосування | |
| ECSP15025357A (es) | Formas de dosificación de ruxolitinib de liberación sostenida |